NCT07902375Recruiting
Methylation Profiling in Self-samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
The goal of the MYSSELF study is to investigate which biological markers (i.e., (epi)genetic biomarkers) found in self-collected samples, such as first-void urine and vaginal samples, are linked to the presence of endometrial, ovarian, vulvar, or vaginal (pre-)cancer or to postmenopausal bleeding. Samples collected by clinicians from the cervix or vulva, as well as blood and tissue samples, will be used for comparison. The study will explore whether these markers could help improve earlier and less invasive detection of gynecological cancers in the future.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 730 (estimated)
- First submitted
- 21 Oct 2026
- Start date
- 19 Jun 2026
- Primary completion date
- 31 Dec 2032
- Lead sponsor
- Universiteit Antwerpen
- Diseases
- Endometrial cancer, Ovarian cancer
- NCT number
- NCT07902375
What you commit to
- Study type: Interventional
- Planned participants: 730
- From 19 Jun 2026 to the primary completion date, 31 Dec 2032
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment for endometrial, ovarian, vulvar, or vaginal (pre-)cancer in the last 6 months before participation in the study
- Participating in another interventional clinical study (where, e.g., a medical device, drug, or vaccine is evaluated) at the same time as participating in this study. Participation in another observational or low-interventional clinical study at the same time is allowed.
- Participant received a blood transfusion two weeks before sample collection
Other illness
- Participants with a history or current evidence of any condition or abnormality that might confound the results of the study, or when it is not in the best interest of the participant to participate, in the opinion of the investigator.
Other
- Individuals that underwent hysterectomy or ovariectomy
- Pregnant individuals or 6 weeks post-partum
- Unable to give informed consent
- Participant has severe anemia
Who the study is looking for
- Individuals having female genital organs, regardless of their gender identity
- 18 years old or older at the time of signing the informed consent form
- Diagnosed with either endometrial, ovarian, vulvar, or vaginal cancer irrespective of stage; diagnosed with one of their precursor lesions; or individuals with postmenopausal bleeding
- Has not started any form of cancer treatment prior to study enrolment
- Written informed consent must be obtained from each participant
- The participant is able to understand the information brochure and what the study is about
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital of Antwerp (UZA) Coordinator of this site? Confirm its status | Edegem | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.